Based on the current available evidence, CAR-T therapy appears to have a generally manageable safety profile in autoimmune diseases, supporting its potential as a promising treatment option for patients with relapsed or refractory autoimmune diseases.
Overall, CAR T cell therapy beyond oncology is promising but remains preliminary, requiring standardized reporting, long-term safety monitoring, scalable manufacturing, and carefully defined risk–benefit thresholds.
Kawther A. Zaher, J. Alrahimi· Pathophysiology· 0 citations
Background: Autoimmune rheumatic diseases (ARDs) are characterized by a failure of immune tolerance, leading to chronic inflammation, autoantibody production, and progressive organ damage. Conventional therapies often fail to induce long-term, drug-free remission in refractory patients. Chimeric antigen receptor (CAR)...
Mateusz Miluski, D. Szydłowska, Mikołaj Jońca et al.· International Journal of Inn...· 0 citations
In vivo chimeric antigen receptor (CAR) T-cell therapy directly programs endogenous T cells within the patient rather than generating the cells through conventional ex vivo manufacturing. While promising, the clinical landscape of this emerging technology is fragmented. Therefore, this systematic review evaluated...
E. Mahmoudi, Faezeh Shokrolahi, Amir Hossein Razmi Khoshkanab et al.· BMC Cancer· 0 citations
With their success in the treatment of various malignancies, immune checkpoint inhibitors (ICIs) are quickly being established as a critical component of treatment plans in oncology. However, due to concerns regarding autoimmune flares and immune-related adverse events, patients with autoimmune disease have historicall...
Jennifer George, Michalah O'Connell, Jonathan Kruger et al.· Sclerosis· 0 citations
Autoimmune diseases are chronic immune-mediated disorders that, in their systemic forms, such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathies, and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), remain associated with progressive organ damage,...
Irviana A. Molina-Garcia, J. Oliverosperez, S. D. Molina-Garcia et al.· Cureus· 0 citations
Autoimmune skin diseases (AISDs) constitute a complex group of conditions whose pathogenesis is based on abnormal activation of the immune system, leading to the production of autoantibodies and damage to skin structures. In recent years, a key role in these processes has been attributed to B lymphocytes, which not onl...
Patryk Brzezicki, Natalia Bębenek, Gabriela Barszcz et al.· International Journal of Inn...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
